Companies/US/BIIB

BIOGEN INC.

Income flow

Annual
BIIB 10-K Income StatementPeriod 2025-12-31Source 10-K
MSProduct Revenues$2BRare Disease Product Revenue$990MRevenues From Anti CD20Therapeutic Programs$855MTysabri Product$765MSpinraza$711MFumarate$655MRoyalty Attributed To OCREVUS$650MInterferon$434MVumerity$343MContract Manufacturing Royalty And Other Revenue$337MBiosimilars$335MAvonex$320MTecfidera$312MContract Manufacturing And Other Revenue$312MSkyclarys$239MBenepali$208MPlegridy$115MOther$91MZurzuvae$90MImraldi$87MAlzheimers Collaboration$82MQalsody$40MRoyalty$25MFlixabi$24MByooviz$15MFUMADERMAnd ADUHELM$964,717Fampyra$643,145Tofidence$321,572Revenue$10B+2% Y/YGross profit$7B+2% Y/YCost of revenue$2BOperating profit$2B-18% Y/YOperating expenses$6BNet profit$1B-21% Y/YTax$264MR&D & other$3BSG&A$2B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$21.5B
  • MSProduct Revenues$4.0B18.8%
  • Rare Disease Product Revenue$2.2B10.0%
  • Revenues From Anti CD20Therapeutic Programs$1.9B8.6%
  • Tysabri Product$1.7B7.7%
  • Spinraza$1.5B7.2%
  • Fumarate$1.4B6.6%
  • Royalty Attributed To OCREVUS$1.4B6.6%
  • Interferon$946M4.4%
  • Vumerity$747M3.5%
  • Contract Manufacturing Royalty And Other Revenue$733M3.4%
  • Biosimilars$729M3.4%
  • Avonex$696M3.2%
  • Tecfidera$680M3.2%
  • Contract Manufacturing And Other Revenue$679M3.2%
  • Skyclarys$521M2.4%
  • Benepali$453M2.1%
  • Plegridy$250M1.2%
  • Other$197M0.9%
  • Zurzuvae$195M0.9%
  • Imraldi$190M0.9%
  • Alzheimers Collaboration$178M0.8%
  • Qalsody$87M0.4%
  • Royalty$54M0.3%
  • Flixabi$53M0.2%
  • Byooviz$32M0.1%
  • FUMADERMAnd ADUHELM$2M0.0%
  • Fampyra$1M0.0%
  • Tofidence$700,0000.0%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).0.00%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).0PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.0.0%Shares outTotal shares currently outstanding (issued and not retired).147.8MFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).147.2M
Stock splits
  1. 3:12001-01-18

Valuation

Trailing PE 20.0 (2025-12-31)PE trend

Fiscal PE5

PeriodEPSClosePE
2025-12-318.79175.9920.0
2024-12-3111.18152.9213.7
2023-12-317.97258.7732.5
2022-12-3120.87276.9213.3
2021-12-3110.4239.9223.1

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.